Breaks Categories: News

TuesdayOct 06, 2020 12:51 pm

BioMedNewsBreaks – Predictive Oncology (NASDAQ: POAI) Shareholder Letter Provides Company Update, Status of Subsidiaries

Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, has released a shareholder letter providing a review of where POAI “stands as of today.” The letter noted that, despite a decline of stock price over the past few weeks, the company’s cash burn is stable and even trending down, and revenues are stable and trending upward. The letter notes that POAI has adequate cash for operation, as well as ability to utilize an equity line of credit of more than $10 million. The letter also provides an update on the…

Continue Reading

TuesdayOct 06, 2020 11:33 am

BioMedNewsBreaks – Genprex Inc. (NASDAQ: GNPX) to Present at Cell and Gene Therapy Sector’s Foremost Annual Conference

Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company developing potentially life-changing technologies for cancer and diabetes patients, today announced that it will present at the Alliance for Regenerative Medicine’s (“ARM”) virtual Cell and Gene Meeting on the Mesa, which is set to take place October 12-16, 2020. Genprex’s executive vice president and COO Michael Redman will lead the company’s presentation. The 2020 event will be delivered in a virtual format over the course of five days and feature on-demand company presentations and live-streaming panels. The Cell and Gene Meeting on the Mesa is the sector’s foremost annual conference, bringing together…

Continue Reading

MondayOct 05, 2020 2:00 pm

BioMedNewsBreaks – 180 Life Sciences Corp. Announces New Board Appointments

KBL Merger Corp. (NASDAQ: KBLM) (KBL Merger Corp. Rights NASDAQ: KBLMR) (KBL Merger Corp. Warrant NASDAQ: KBLMW), a Special Purpose Acquisition Corporation (SPAC) that has signed a detailed merger agreement with 180 Life Sciences Corp., a clinical-stage biotechnology company, recently announced the appointment of Professor Richard Barker, Larry Gold Md., Shoshana Shendelman PhD., and Donald McGovern Jr. to its board of directors, upon completion of the business combination. 180 Life Sciences is led by Dr. James Woody, who previously served as the founding CEO of OncoMed Pharmaceuticals and president and general manager of Roche Bioscience. “I’m pleased to welcome Richard,…

Continue Reading

MondayOct 05, 2020 11:46 am

BioMedNewsBreaks – LexaGene Holdings, Inc. (TSX.V: LXG) (OTCQB: LXXGF) Issues Corporate Update

LexaGene Holdings (TSX.V: LXG) (OTCQB: LXXGF), a molecular diagnostics company that develops fully automated rapid pathogen detection systems, today provided a general corporate update. Among highlights provided in the update, LexaGene is in a strong position to support its development goals for the next year and beyond with its treasury currently standing at US$11.3 million (C$14.9 million). “Our MiQLab(TM) pathogen detection system has 230 unique components. Over the summer, the coronavirus pandemic caused some supply chain issues for several key components that delayed the manufacturing, optimization and testing of these systems. Just recently, these supply chain issues were resolved and…

Continue Reading

FridayOct 02, 2020 10:18 am

BioMedNewsBreaks – Processa Pharmaceuticals Inc. (NASDAQ: PCSA) Announces Pricing of $19.2M Public Offering, Nasdaq Uplisting

Processa Pharmaceuticals (NASDAQ: PCSA), a clinical-stage biopharmaceutical company focused on the development of drug products for patients with high unmet medical need conditions or no alternative treatment options, today announced the pricing of an underwritten public offering of 4,800,000 shares of common stock for a price to the public of $4.00 per share. Processa expects approximately $19.2 million in gross proceeds and announced that, in connection with the offering, its common stock has been approved for listing on the Nasdaq Capital Market with commencement of trading under the symbol “PCSA” on October 2, 2020. The offering is expected to close…

Continue Reading

ThursdayOct 01, 2020 12:22 pm

BioMedNewsBreaks – MediXall Group Inc. (MDXL) Launches New Telehealth Solutions for Uninsured, Underinsured

MediXall Group (OTCQB: MDXL), a technology and innovation-driven organization focused on reducing costs of health care and transforming the patient-provider experience through the launch of its Health Karma(TM) platform, today announced new virtual-care solutions for the uninsured and underinsured. Effective immediately, Americans can conduct an online medical visit with a board-certified medical professional to get fast and easy treatment, prescriptions and lab tests for routine medical issues. This new service is a result of Health Karma’s recent partnership with leading telehealth company MeMD. “Telehealth will continue to be a popular option for patients, providers and employers beyond the pandemic,” Health…

Continue Reading

ThursdayOct 01, 2020 10:38 am

BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Achieves Critical Milestone for Production of Lead Drug Candidate

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers of the brain and central nervous system, today announced that its GMP manufacturer partner NCK A/S, received a Certificate of Analysis (“CoA”) for its Active Pharma Ingredient (“API”), clearing it for use in the production of Berubicin. CNS Pharmaceuticals previously announced entry into a contract with NCK A/S, a GMP manufacturer of complex drugs and the previous producer of Berubicin for Reata Pharmaceuticals, for the large-scale production of Berubicin, CNSP’s lead drug candidate for the treatment of glioma brain tumors. "We…

Continue Reading

ThursdayOct 01, 2020 9:55 am

BioMedNewsBreaks – VistaGen Therapeutics (NASDAQ: VTGN) CEO Discusses ‘Sea of Change’ to Future of Anxiety Treatment

VistaGen Therapeutics’ (NASDAQ: VTGN) CEO Shawn Singh authored a recent article for Life Science Leader titled, “The Future of Anxiety Treatment Will Be Drastically Different.” In the piece, Singh, an experienced professional who has dedicated over 25 years to biopharma and medical device industries, addresses the current standard of care for anxiety disorders and its inability to meet the growing need. “As researchers learn more about psychological therapy for anxiety disorders and medication options to complement it, efforts are underway to develop innovative medications to displace current anti-anxiety drugs that are not effective for all patients and are associated with…

Continue Reading

WednesdaySep 30, 2020 9:35 am

BioMedNewsBreaks – VistaGen Therapeutics (NASDAQ: VTGN) CEO Addresses ‘Multi-Pronged Approach’ to Growing Problem of Workplace Stress and Anxiety

VistaGen Therapeutics’ (NASDAQ: VTGN) CEO Shawn Singh authored a recent article for Business.com regarding the COVID-19 pandemic and resulting stress and anxiety impacts to the workplace. In the piece, Singh indicates that stress and anxiety, often driven by job-related issues, when left unchecked can rise to the level of an anxiety disorder with negative consequences for physical health, mental well-being, productivity and career opportunities. The global pandemic has exacerbated this largely unaddressed and widespread mental health problem in the workplace, markedly reflecting in increased prescriptions for antidepressant and anti-anxiety medications, many associated with significant side effects and safety concerns. “To…

Continue Reading

MondaySep 28, 2020 11:54 am

BioMedNewsBreaks – VistaGen Therapeutics (NASDAQ: VTGN) Featured in Equity Research Company Update

VistaGen Therapeutics (NASDAQ: VTGN), a biopharmaceutical company developing new generation medicines for anxiety, depression and other central nervous system (“CNS”) disorders, was featured in an Equity Research Company Update by Maxim Group LLC. The report, titled “Benzo-Benefits Without the Benzo-Baggage – The Case for PH94B Builds,” highlights potential benefits of VistaGen’s PH94B drug candidate, a nasal spray designed for treatment of adults with social anxiety disorder, as compared to treatment with benzodiazepines. The report reads, “Benzodiazepines (benzos) have been available to treat anxiety since the 1960s, and include well-known products such as Xanax, Ativan, and Klonopin. These drug compounds work…

Continue Reading